Claims for Patent: 10,195,273
✉ Email this page to a colleague
Summary for Patent: 10,195,273
Title: | Selectively altering microbiota for immune modulation |
Abstract: | The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration. |
Inventor(s): | Clube; Jasper (London, GB) |
Assignee: | SNIPR TECHNOLOGIES LIMITED (London, GB) |
Application Number: | 15/820,296 |
Details for Patent 10,195,273
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Llc | KEYTRUDA | pembrolizumab | For Injection | 125514 | September 04, 2014 | ⤷ Try for Free | 2036-06-05 |
Merck Sharp & Dohme Llc | KEYTRUDA | pembrolizumab | Injection | 125514 | January 15, 2015 | ⤷ Try for Free | 2036-06-05 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | December 22, 2014 | ⤷ Try for Free | 2036-06-05 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | October 04, 2017 | ⤷ Try for Free | 2036-06-05 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | August 27, 2021 | ⤷ Try for Free | 2036-06-05 |
Genentech, Inc. | TECENTRIQ | atezolizumab | Injection | 761034 | May 18, 2016 | ⤷ Try for Free | 2036-06-05 |
Genentech, Inc. | TECENTRIQ | atezolizumab | Injection | 761034 | March 08, 2019 | ⤷ Try for Free | 2036-06-05 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |